YU31502A - Kristali kao inhibitori natrijum-vodonik izmenjivača tip1 - Google Patents

Kristali kao inhibitori natrijum-vodonik izmenjivača tip1

Info

Publication number
YU31502A
YU31502A YU31502A YUP31502A YU31502A YU 31502 A YU31502 A YU 31502A YU 31502 A YU31502 A YU 31502A YU P31502 A YUP31502 A YU P31502A YU 31502 A YU31502 A YU 31502A
Authority
YU
Yugoslavia
Prior art keywords
sodium
exchanger type
inhibitor
hydrogen exchanger
nhe
Prior art date
Application number
YU31502A
Other languages
English (en)
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU31502A publication Critical patent/YU31502A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Kristali inhibitori NHE-1, postupci za upotrebu takvih kristala inhibitora NHE-1 i farmaceutske kompozicije koje sadrže takve kristale inhibitore NHE-1. Kristali inhibitori NHE-1 su korisni za smanjenje oštećenja tkiva do koga dolazi usled ishemije tkiva.[NHE-1 inhlbitor crystal of Formula (I), methods of using such NHE-1 inhibitor crystal and pharmaceutical compositions containing such NHE-1 inhibitor crystal. The NHE-1 inhibitor crystal is useful for the reduction of tissue damage resulting from tissue ischemia.
YU31502A 1999-10-29 2000-10-09 Kristali kao inhibitori natrijum-vodonik izmenjivača tip1 YU31502A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
YU31502A true YU31502A (sh) 2004-12-31

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
YU31502A YU31502A (sh) 1999-10-29 2000-10-09 Kristali kao inhibitori natrijum-vodonik izmenjivača tip1

Country Status (44)

Country Link
EP (1) EP1224179B1 (sh)
JP (1) JP2003512455A (sh)
KR (1) KR100464526B1 (sh)
CN (2) CN1205205C (sh)
AP (1) AP2002002493A0 (sh)
AR (1) AR029402A1 (sh)
AT (1) ATE271047T1 (sh)
AU (1) AU778573B2 (sh)
BG (1) BG106729A (sh)
BR (1) BR0015275A (sh)
CA (1) CA2389020A1 (sh)
CO (1) CO5271714A1 (sh)
CZ (1) CZ20021332A3 (sh)
DE (1) DE60012208T2 (sh)
DK (1) DK1224179T3 (sh)
DZ (1) DZ3463A1 (sh)
EA (1) EA004937B1 (sh)
EE (1) EE200200227A (sh)
ES (1) ES2222923T3 (sh)
GE (1) GEP20043222B (sh)
GT (1) GT200000180A (sh)
HK (1) HK1048472B (sh)
HR (1) HRP20020366B1 (sh)
HU (1) HUP0204009A3 (sh)
IL (1) IL148581A0 (sh)
IS (1) IS6302A (sh)
MA (1) MA26840A1 (sh)
MX (1) MXPA02004358A (sh)
NO (1) NO20021821D0 (sh)
NZ (1) NZ517738A (sh)
OA (1) OA12080A (sh)
PA (1) PA8505501A1 (sh)
PE (1) PE20010764A1 (sh)
PL (1) PL354869A1 (sh)
PT (1) PT1224179E (sh)
SI (1) SI1224179T1 (sh)
SK (1) SK5312002A3 (sh)
SV (1) SV2002000209A (sh)
TN (1) TNSN00210A1 (sh)
TR (1) TR200201167T2 (sh)
UA (1) UA72002C2 (sh)
WO (1) WO2001030759A2 (sh)
YU (1) YU31502A (sh)
ZA (1) ZA200203295B (sh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
YU51903A (sh) * 2001-01-31 2006-05-25 Pfizer Products Inc. Enolati inhibitora izmene natrijum-vodonik tipa-1
CA2472342A1 (en) * 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030083004A (ko) * 1998-02-27 2003-10-23 화이자 프로덕츠 인크. 허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화고리)카르보닐] 구아니딘 유도체

Also Published As

Publication number Publication date
WO2001030759A2 (en) 2001-05-03
WO2001030759A3 (en) 2001-09-13
EP1224179A2 (en) 2002-07-24
MXPA02004358A (es) 2002-11-07
SK5312002A3 (en) 2003-01-09
HUP0204009A2 (hu) 2003-03-28
JP2003512455A (ja) 2003-04-02
NO20021821L (no) 2002-04-18
BG106729A (bg) 2002-12-29
NO20021821D0 (no) 2002-04-18
CZ20021332A3 (cs) 2002-10-16
PT1224179E (pt) 2004-10-29
AU7441500A (en) 2001-05-08
IS6302A (is) 2002-03-15
PE20010764A1 (es) 2001-07-23
AR029402A1 (es) 2003-06-25
HUP0204009A3 (en) 2004-07-28
AU778573B2 (en) 2004-12-09
DK1224179T3 (da) 2004-10-25
CN1636991A (zh) 2005-07-13
OA12080A (en) 2003-08-25
CA2389020A1 (en) 2001-05-03
SI1224179T1 (en) 2004-10-31
GT200000180A (es) 2002-04-11
ZA200203295B (en) 2003-06-25
KR20020040918A (ko) 2002-05-30
AP2002002493A0 (en) 2002-06-30
ES2222923T3 (es) 2005-02-16
HRP20020366A2 (en) 2004-02-29
EE200200227A (et) 2003-06-16
DZ3463A1 (fr) 2001-05-03
ATE271047T1 (de) 2004-07-15
CO5271714A1 (es) 2003-04-30
TR200201167T2 (tr) 2002-08-21
MA26840A1 (fr) 2004-12-20
CN1205205C (zh) 2005-06-08
KR100464526B1 (ko) 2005-01-03
BR0015275A (pt) 2002-07-16
EA200200416A1 (ru) 2002-10-31
EP1224179B1 (en) 2004-07-14
IL148581A0 (en) 2002-09-12
DE60012208D1 (de) 2004-08-19
HK1048472B (zh) 2005-09-16
SV2002000209A (es) 2002-07-16
UA72002C2 (en) 2005-01-17
PL354869A1 (en) 2004-03-08
HRP20020366B1 (en) 2005-04-30
PA8505501A1 (es) 2003-09-05
CN1384829A (zh) 2002-12-11
EA004937B1 (ru) 2004-10-28
TNSN00210A1 (fr) 2005-11-10
HK1048472A1 (en) 2003-04-04
GEP20043222B (en) 2004-04-26
NZ517738A (en) 2005-06-24
DE60012208T2 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
AP9901478A0 (en) Compounds for the treatment of ischemia.
IL126610A0 (en) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors
SI1109787T1 (sl) Arilpiperazini in njihova uporaba kot metaloproteinazo inhibirajoca sredstva (MMP)
CA2260337A1 (en) Therapeutic agents
CA2318145A1 (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
AP2002002531A0 (en) 4-Carboboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inihibitor.
ES2136037A1 (es) Inhibidores de sulfamida-metaloproteasa
SE9602646D0 (sv) Pharmaceutically-useful compounds
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DE69625505T2 (de) Guanidino proteiase inhibitoren
BG104575A (en) Matrix metalloprotease inhibitors
YU31502A (sh) Kristali kao inhibitori natrijum-vodonik izmenjivača tip1
YU79602A (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
DE69405760D1 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
MXPA04004685A (es) Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno.
WO2004006927A3 (en) Sulphonylpiperidine derivatives containing an alkenyl or alkynly moiety for use as matrix metalloproteinase inhibitors
FI955707A (fi) Indolijohdannaiset steroidi-5alfa-reduktaasin inhibiittoreina
YU62900A (sh) Postupak za dobijanje inhibitora za tip 1 izmenjivača natrijum-vodonik
BR9807920A (pt) Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência